Extended Data Table 1 Patient baseline characteristics

From: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

  1. 20 patients were screened to participate in the clinical trial, 16 of which were found to be eligible according to the inclusion and exclusion criteria, and enrolled into the study. For mutational profile of individual patients see Extended Data Fig. 1. Two patients withdrew their consent and one patient could not start the study treatment owing to newly diagnosed, rapidly progressing brain metastases. The table lists the tumour mutation profiles of the 13 patients who received neo-epitope RNA vaccine. FF, fresh frozen; FFPE, formalin-fixed, paraffin-embedded; ns, non-synonymous; SNVs, single-nucleotide variants.
Back to article page